Maysa Abu Khalaf, MD

Maysa Abu Khalaf, MD

Contact Dr. Abu Khalaf

1025 Walnut Street
Suite 700
Philadelphia, PA 19107

(215) 503-5088
(215) 503-3408 fax

Most Recent Peer-reviewed Publications

  1. PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer
  2. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer
  3. Chemotherapy Agents With Known Cardiovascular Side Effects and Their Anesthetic Implications
  4. Impacts of early guideline-directed 21-gene recurrence score testing on adjuvant therapy decision making
  5. Racial and ethnic disparities in oncotype DX test receipt in a statewide population-based study
  6. A Case of Carcinocythemia: De Novo Hormone Receptor-positive Metastatic Breast Cancer Presenting With Circulating Tumor Cells Mimicking an Acute Leukemia
  7. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer
  8. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition
  9. Immune signatures following single dose trastuzumab predict pathologic response to preoperativetrastuzumab and chemotherapy in HER2-positive early breast cancer
  10. Patient preferences regarding incidental genomic findings discovered during tumor profiling
  11. New strategies in breast cancer: Immunotherapy
  12. Mutation based treatment recommendations from next generation sequencing data: A comparison of web tools
  13. Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer
  14. Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008–2011
  15. Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancers
  16. Relationship between complete pathologic response to neoadjuvant chemotherapy and survival in triple-negative breast cancer
  17. Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma
  18. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer
  19. Use of neoadjuvant chemotherapy for patients with stage i to III breast cancer in the United States
  20. Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy